argenx
Agent32Agent Readiness: 32/100. Below median. Measured by StartupHub.ai. Median 41.Global immunology company developing antibody-based therapies for severe autoimmune diseases.
About
Argenx is a global, commercial-stage biopharmaceutical company focused on developing and delivering transformative therapies for patients with severe autoimmune diseases. They leverage their expertise in immunology and antibody engineering to create a pipeline of novel antibody-based medicines, with a flagship product, Vyvgart (efgartigimod alfa), approved for conditions like generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Key facts
At-a-glance profile data
- Website
- argenx.com
- Headquarters
- Amsterdam, Netherlands
- Founded
- 2008
- Total funding
- $51M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Jan 2011 | Series B | $37M | - |
| 1 Jan 2009 | Series A | $14M | Forbion, EQT Life Sciences, Kurma Partners |
Tech stack
Detected on argenx.com and in its job posts, last scanned 18 Oct 2026. Run your own scan
- Frontend
- Bootstrap
- Backend
- Python
- Analytics
- Google Tag Manager
- Email provider
- Mimecast
- Hiring platform
- Workday
- Video / media
- Vimeo
Frequently asked
How much funding has argenx raised?
argenx has raised a total of $51M in funding. The most recent round on record is Series B.